Tech and Pharma Stocks Are “Most Attractive” for December

The Decem­ber ver­sion of our Most Attrac­tive Stocks report is now avail­able. Note that Barron’s recently rec­og­nized our Most Attrac­tive Stocks port­fo­lio as #1 over the prior 12 months amongst the best of the Wall Street research firms.

Lots of tech and pharma stocks make this month’s list. For example, Microsoft (MSFT) and Analog Devices (ADI) make the cut for the large cap Most Attractive this month. We also like China Biotics (CHBT) , Safe Bulkers (SB) and Surmodics (SRDX) on the small cap list. All of these stocks get our “very attractive” rating, which mean they have high quality economic earnings and their valuations are cheap. For example, the current stock prices of MSFT and ADI imply those companies profits will decline permanently by 10% or more. The current stock prices of CHBT, SB and SRDX imply those companies profits will decline permanently by 50% or more. The low expectations in the stock prices of these stocks provide investors attractive downside protection and upside potential.

Note that we offer free com­pany val­u­a­tion reports for 4 of the com­pa­nies included in our Most Attrac­tive and Most Dan­ger­ous Stocks newsletters.

Here is a quick overview for the Decem­ber reports.

• 7 new stocks make our Decem­ber lists.
• The Most Attrac­tive Stocks port­fo­lio (-1.2%) out­per­formed the S&P 500 (-1.5%) last month.
• Most Attrac­tive Stocks have high and ris­ing returns on cap­i­tal (ROIC) and low mar­ket expec­ta­tions for future profits.